Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine (CD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01153490|
Recruitment Status : Completed
First Posted : June 30, 2010
Last Update Posted : April 17, 2018
Cannabis is the most used illicit substance in the United States. Previous studies suggest that atypical antipsychotics decrease the frequency and the amount of substance use in subjects with and without psychotic illness. So far, there are no controlled studies assessing the effectiveness of atypical antipsychotics for decreasing cannabis and other substance use in individuals with cannabis use disorders. The investigators postulate that the atypical antipsychotic quetiapine ER is an effective agent for improving substance use outcomes in subjects with cannabis use disorders. In this pilot study, the investigators will test this hypothesis in heavy cannabis users (i.e., individuals who are cannabis dependent and smoke three times or more per week). Because 50% of these heavy cannabis users report histories of psychotic experiences (i.e., attenuated positive symptoms) while smoking and are at risk for recurring psychotic symptoms, the investigators will focus this pilot clinical trial on this subgroup of cannabis users in order to increase the risk/benefit ratio of this study and target a population that may also benefit from the antipsychotic effect of quetiapine ER. Considering the lack of controlled studies assessing the efficacy of atypical antipsychotics in heavy cannabis users, assessing the effectiveness of an atypical antipsychotic medication on substance use and clinical outcomes in this population is critical for improving the prognosis of these individuals.
Thus, the aims of this randomized, double-blind, placebo-controlled study are to assess the efficacy of an atypical antipsychotic (quetiapine ER) in 120 subjects with cannabis dependence, a recent history (within a year) of attenuated psychotic symptoms, and using cannabis 3 times or more per week for: (1) decreasing the use of cannabis and other substances; and (2) preventing the recurrence of psychotic experiences. The investigators will also assess the effects of quetiapine ER on craving and mood, and its tolerability. This project will be a 12-week, randomized, double-blind, placebo-controlled study with quetiapine ER and it will include a comprehensive assessment of symptoms, substance use, and side effects.
This study will benefit the field by providing unique data on the relative efficacy and tolerability of treatment with atypical antipsychotics in heavy cannabis users with a vulnerability to psychosis. This study will be the basis for future studies assessing the long-term efficacy and tolerability of atypical antipsychotics in individuals with cannabis use disorders.
|Condition or disease||Intervention/treatment||Phase|
|Cannabis Dependence||Behavioral: Behavioral Intervention||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||124 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine|
|Actual Study Start Date :||October 22, 2010|
|Actual Primary Completion Date :||August 6, 2012|
|Actual Study Completion Date :||August 6, 2012|
|Placebo Comparator: Placebo||
Behavioral: Behavioral Intervention
|Active Comparator: Quetiapine ER||
Behavioral: Behavioral Intervention
- Frequency/amount of substance use [ Time Frame: 12 weeks ]frequency and amount of cannabis and other substance use will be recorded with the Timeline Follow-Back Method.
- Psychotic symptoms [ Time Frame: 12 weeks ]Psychotic symptoms wil be assessed with the Structured Interview for Prodromal Symptoms and the Brief Psychiatric Rating Scale.
- Craving [ Time Frame: 12 weeks ]Craving will be assessed with the Marijuana Craving Questionnaire and a Visual Analog Craving Scale
- Mood symptoms [ Time Frame: 12 weeks ]Mood symptoms will be assessed with the Hamilton Depression Rating Scale
- Adverse events [ Time Frame: 12 weeks ]Adverse events will be assessed with the Systematic Assessment for Treatment Emergent Events interview, Simpson-Angus Scale for Extrapyramidal Symptoms, the Abnormal Involuntary Movement Scale, the Barnes Akathisia Scale, and blood tests (fasting glucose, insulin and lipid profile tests)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01153490
|United States, New York|
|The Zucker Hillside Hospital|
|Glen Oaks, New York, United States, 11004|
|General Clinical Research Center|
|Manhasset, New York, United States, 11030|
|Principal Investigator:||Serge Sevy, M.D., MBA||Feinstein Institute for Medical Research|